VivaTech 2019: Thales Receives Global Innovator Award and Invites Visitors to Be Astronauts for a Day
7.5.2019 08:00:00 EEST | Business Wire | Press release
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005645/en/
"Thales Alenia Space". Copyright: Thales
Global recognition for research and innovation
The Derwent Top 100 Global Innovators ranking recognises the volume, success and influence of the patents filed by technology companies. Thales has appeared six times in this prestigious ranking, reflecting the company’s commitment to innovating, bringing inventions to market and protecting its ideas.
This distinction comes at a turning point in Thales’s history. With the completion of the acquisition of Gemalto on 2 April, the Group now employs 28,000 engineers, devotes €1 billion a year to self-funded R&D and maintains a portfolio of 20,500 patents, including 400 filed in 2018. At the show, Thales will also sign the LGBT+ Charter championed by Autre Cercle, thus highlighting the group’s strategy of promoting diversity and inclusion across its talent pool, as a way to free creative potential and foster innovation.
Thales at VivaTech: AI for every decisive moment
Thales will be showcasing its latest innovations alongside some 30 start-ups from six countries specialising in artificial intelligence, connectivity, drone technology, cybersecurity and robotics.
A series of demonstrations will show how advanced technology helps real-life users to understand the most complex situations:
- Columbus invites visitors to feel what it’s like to be an astronaut on-board the International Space Station’s science laboratory.
- The autonomous train demonstrator lets visitors drive a New York City subway train and see how they match up to the capabilities of artificial intelligence.
- Piume allows users to experience what it’s like to be an explorer or a researcher working in harsh environments.
- Geonav uses the Galileo satellite constellation to prevent risks faced by high-level athletes, without the dropped signals that often occur inside sports stadiums.
- Smart New World combines the power of holographic displays with IoT (Internet of Things) technology.
- The 3D interactive hologram table developed with the Australian start up Euclideon models anything you can imagine: cities, objects, design techniques and much more.
Thales experts will also be taking part in around 40 panel sessions to discuss how artificial intelligence that is trustable, explainable and certifiable can be used to invent or reinvent the cities of the future, develop autonomous trains and future medical imaging solutions, protect the environment and take space exploration to the next frontier. The schedule for the demonstrations and panel sessions can be found on the Thales event website.
Thales Decisive Journeys at VivaTech
- DecisiveJourney#1: From space observation to personal data protection: find out how trusted AI is a decisive technology for Thales
- DecisiveJourney#2: Thales technologies applied to environmental protection
- DecisiveJourney#3: Artificial nano-neurons and medical imaging: Thales innovations reshaping the future of medicine
- DecisiveJourney#4: How to develop responsible AI
- DecisiveJourney#5: How digital is changing our companies and work methods
About Thales
The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018
PLEASE VISIT
Thales
Group
Twitter: @Thalesgroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005645/en/
Contact information
Thales, Media Relations
Alice Pruvot +33 (0)7 70 27 11 37
alice.pruvot@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
euNetworks launches new quantum-safe private connectivity service powered by Adtran’s encrypted optical transport technology27.5.2026 11:00:00 EEST | Press release
Adtran and euNetworks today announced their collaboration on the launch of a new quantum-safe private connectivity service, Quantum Shield. euNetworks has developed Quantum Shield using Adtran’s optical transport technology to augment its broader architecture, which is designed to deliver secure, scalable data center connectivity across euNetworks’ pan-European network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526610601/en/ Adtran’s encrypted optical transport technology is helping euNetworks deliver the highest levels of protection for sensitive data moving across Europe. The new offering is built for enterprises with stringent security, performance and customer-controlled encryption requirements. The deployment combines high-capacity dedicated infrastructure with real-time fiber monitoring and enhanced optical-layer visibility to safeguard critical traffic. By integrating advanced encryption with continuous monito
National Bank of Greece in Cyprus Goes Live With Smartstream’s Air to Consolidate Reconciliations27.5.2026 10:55:00 EEST | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that the National Bank of Greece (NBG) in Cyprus has successfully gone live with Air, the company’s AI-enabled reconciliation solution. The go-live marks a significant step forward in the bank’s operational efficiency, reducing daily manual processing effort and eliminating the complexity of working across multiple data formats. The bank has deployed Air’s Cash module, replacing both incumbent and consolidating four separate reconciliation systems for Instant, Cash, SEPA, and Nostro reconciliations, into a single, intelligent platform. Although transaction volumes were manageable, the fragmented landscape required significant daily manual effort to handle items individually across each system and to navigate multiple data formats. Following a market review, the bank committed to Smartstream’s Air, with self service model and AI-enabled automation being a distinct
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 10:20:00 EEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release
Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom